PF-04531083 + PF-04531083 + Ibuprofen
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-surgical Dental Pain
Conditions
Post-surgical Dental Pain
Trial Timeline
Oct 1, 2011 → May 1, 2012
NCT ID
NCT01512160About PF-04531083 + PF-04531083 + Ibuprofen
PF-04531083 + PF-04531083 + Ibuprofen is a phase 2 stage product being developed by Pfizer for Post-surgical Dental Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT01512160. Target conditions include Post-surgical Dental Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512160 | Phase 2 | Terminated |
Competing Products
5 competing products in Post-surgical Dental Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + Placebo | Pfizer | Phase 3 | 76 |
| valdecoxib + valdecoxib/placebo + placebo | Pfizer | Phase 3 | 76 |
| Dexamethasone | Ocular Therapeutix | Phase 3 | 72 |
| Dexamethasone | Ocular Therapeutix | Phase 3 | 72 |